Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea. Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration, or nAMD, aiming to prevent disease-related blindness. Afqlir is one of several biosimilar value drivers for Sandoz and this approval represents a major step in advancing the company’s growth strategy. Launch is expected as of Q4 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz price target raised to CHF 36 from CHF 33 at Deutsche Bank
- Sandoz price target raised to CHF 39 from CHF 38 at Berenberg
- Sandoz price target raised to CHF 42 from CHF 40 at RBC Capital
- Sandoz price target raised to CHF 35 from CHF 32 at Morgan Stanley
- Sandoz price target raised to CHF 43 from CHF 36.50 at JPMorgan